Indiana is currently home to 1209 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Indianapolis, South Bend, Fort Wayne and Evansville. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
NCT03191149
Recruiting
This phase II trial studies how well osimertinib works in treating patients with non-small cell lung cancer with EGFR exon 20 insertion mutation that is stage IIIB-IV or has come back after a period of improvement (recurrent). Osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/19/2025
Locations: Reid Health, Richmond, Indiana
Conditions: Advanced Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IIIB Lung Non-Small Cell Cancer AJCC v7, Stage IV Lung Non-Small Cell Cancer AJCC v7
Register for Updates
Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers)
NCT07003919
Recruiting
The primary objective of this study is to assess the 6-month safety of DBV712 250 micrograms (mcg) in subjects 1 through 3 years of age with peanut allergy.
Gender:
ALL
Ages:
Between 1 year and 3 years
Trial Updated:
07/18/2025
Locations: Deaconess Clinic - Downtown Evansville, Evansville, Indiana
Conditions: Allergy, Peanut Allergy
Register for Updates
A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)
NCT06858579
Recruiting
The purpose of this Phase 3 study is to demonstrate the efficacy of DNTH103 as compared to placebo in participants with chronic inflammatory demyelinating polyneuropathy (CIDP).
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
07/18/2025
Locations: Clinical Study Site, Indianapolis, Indiana
Conditions: Chronic Inflammatory Demyelinating Polyneuropathy
Register for Updates
Innovative Automated Insulin Delivery System for Type 2 Diabetes
NCT06853990
Recruiting
The goal of this clinical trial is to learn if the twiist insulin delivery system works to treat adults with insulin-treated type 2 diabetes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/18/2025
Locations: IU Health University Hospital, Indianapolis, Indiana
Conditions: Type 2 Diabetes, Insulin Treated Type 2 Diabetes Mellitus
Register for Updates
Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma
NCT06585410
Recruiting
This study will test a study drug called cemiplimab to see if it can help treat early-stage cutaneous squamous cell carcinoma (CSCC), a type of skin cancer. Cemiplimab works by helping the immune system to kill cancer cells. It binds to a protein called programmed cell death-1 (PD-1) on the surface of certain immune cells. The main purpose of this study is to compare how well cemiplimab works compared to surgery, when injected into the lesion. The study is looking at: * The side effects cemip... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/18/2025
Locations: Dawes Fretzin Clinical Research - Shadeland Ave., Indianapolis, Indiana
Conditions: Cutaneous Squamous Cell Carcinoma (CSCC)
Register for Updates
Study to Investigate Changes in Airway Inflammation, Symptoms, and Rescue Therapy Utilization With AIRSUPRA Compared to Albuterol as Needed in Adults With Mild Asthma
NCT06563102
Recruiting
The purpose of this study is to compare the efficacy and safety of albuterol/budesonide to albuterol in changes in airway inflammation, asthma symptoms, and rescue therapy utilization in adults with mild asthma. Study details include: * The study duration will be up to 15 weeks. * The treatment duration will be 12 weeks. * The visit frequency will be once every 4 weeks, with 3 clinic visits and 2 video calls in total.
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
07/18/2025
Locations: Research Site, Plainfield, Indiana
Conditions: Mild Asthma
Register for Updates
Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal Cancer
NCT06493019
Recruiting
A single arm phase II study of pembrolizumab, carboplatin, paclitaxel, and radiation for the treatment of early-stage anal cancer. There are 2 treatments phases and then surveillance. The first treatment phase is the chemoradiation phase (Cycle 1-6, weekly cycles) which is followed by the maintenance phase (Cycle 7-14, 6 week cycles).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/18/2025
Locations: Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana
Conditions: Anal Cancer
Register for Updates
Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)
NCT06456346
Recruiting
The purpose of this study is to evaluate the efficacy and safety of bomedemstat compared with hydroxyurea in cytoreductive therapy naïve essential thrombocythemia (ET) participants for whom cytoreductive therapy is indicated. Its primary objective is to compare bomedemstat to hydroxyurea with respect to durable clinicohematologic response (DCHR). The primary hypothesis is that bomedemstat is superior to hydroxyurea with respect to DCHR.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/18/2025
Locations: Parkview Research Center at Parkview Regional Medical Center ( Site 0006), Fort Wayne, Indiana
Conditions: Essential Thrombocythemia
Register for Updates
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
NCT06393374
Recruiting
This is a randomized, open-label study comparing the efficacy and safety of adjuvant sacituzumab tirumotecan (MK-2870) in combination with pembrolizumab compared to treatment of physician's choice (TPC) in participants with triple-negative breast cancer (TNBC) who received neoadjuvant therapy and did not achieve a pathological complete response (pCR) at surgery. The primary objective is to compare sacituzumab tirumotecan plus pembrolizumab to TPC (pembrolizumab or pembrolizumab plus capecitabine... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/18/2025
Locations: Northwest Cancer Center - Dyer Clinic ( Site 0097), Dyer, Indiana
Conditions: Triple-Negative Breast Cancer
Register for Updates
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
NCT06312137
Recruiting
This study will assess if adding sacituzumab tirumotecan with pembrolizumab after surgery is effective in treating NSCLC for participants not achieving pathological complete response. The primary hypothesis of this study is sacituzumab tirumotecan plus pembrolizumab is superior to pembrolizumab monotherapy with respect to disease free survival (DFS) as assessed by blinded independent central review (BICR).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/18/2025
Locations: Indiana University Health Arnett Cancer Center ( Site 0076), Lafayette, Indiana
Conditions: Non Small Cell Lung Cancer
Register for Updates
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
NCT06283966
Recruiting
This study will evaluate the effect of triple ICS/LAMA/LABA therapy with BGF MDI 320/14.4/9.6 μg on cardiopulmonary outcomes relative to LAMA/LABA therapy with GFF MDI 14.4/9.6 μg in a population with COPD and elevated cardiopulmonary risk.
Gender:
ALL
Ages:
Between 40 years and 80 years
Trial Updated:
07/18/2025
Locations: Research Site, Valparaiso, Indiana
Conditions: COPD (Chronic Obstructive Pulmonary Disease)
Register for Updates
A Trial to Learn if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma
NCT06149286
Recruiting
This study is researching an experimental drug called odronextamab (referred to as study drug), in combination with lenalidomide. The study is focused on participants who have one of two types of cancer: follicular lymphoma (FL) or marginal zone lymphoma (MZL) that has come back after treatment (called "relapsed"), or did not respond to treatment (called "refractory"). FL and MZL are subtypes of Non-Hodgkin 's lymphoma (NHL). This study will be made up of two parts (Part 1 not randomized, Part... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/18/2025
Locations: Indiana University and Comprehensive Cancer Center, Indianapolis, Indiana
Conditions: Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma (MZL)
Register for Updates